A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
A phase 2 trial of Botensilimab in colorectal cancer, run by Agenus Inc., active and no longer recruiting.
Overview
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer is a phase 2 interventional study registered as NCT05608044 by Agenus Inc., with 234 participants enrolled, started 2022-11-30 and due to reach its primary completion in 2027-09. Interventions recorded: Botensilimab, Balstilimab, Standard of Care. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Setting
A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
Phase
Phase 2
Sponsor
Agenus Inc.
Registry
Enrolled
234
Similar pages
not linked directly; found by shared links- TrialVorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Shares Balstilimab, Agenus, Colorectal cancer.
- TrialPhase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can
Shares Botensilimab, Colorectal cancer.
- TrialA Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Shares Balstilimab, Agenus.
- TargetCTLA-4
Shares Botensilimab, Agenus, Colorectal cancer.